|
Volumn 29, Issue 2, 1994, Pages 373-377
|
Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid
a a d a c b |
Author keywords
Bioreductive drug; Dimethylxanthenone acetic acid; Flavone acetic acid; Hypoxia; MDAH MCa 4 tumor; SN 23862; SR 4233; Vasoactive
|
Indexed keywords
5,6 DIMETHYLXANTHENONE 4 ACETIC ACID;
MITOFLAXONE;
NITROBENZENE DERIVATIVE;
SN 23862;
TIRAPAZAMINE;
UNCLASSIFIED DRUG;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANIMAL TISSUE;
ANTINEOPLASTIC ACTIVITY;
BREAST TUMOR;
CANCER INHIBITION;
CONFERENCE PAPER;
DOSE TIME EFFECT RELATION;
DRUG POTENCY;
DRUG POTENTIATION;
INTRAPERITONEAL DRUG ADMINISTRATION;
MOUSE;
NONHUMAN;
PRIORITY JOURNAL;
TUMOR BLOOD FLOW;
ANILINE MUSTARD;
ANIMAL;
ANTINEOPLASTIC AGENTS;
DRUG SYNERGISM;
FEMALE;
FLAVONES;
MAMMARY NEOPLASMS, EXPERIMENTAL;
MICE;
MICE, INBRED C3H;
REGIONAL BLOOD FLOW;
SUPPORT, NON-U.S. GOV'T;
SUPPORT, U.S. GOV'T, P.H.S.;
TRIAZINES;
XANTHENES;
|
EID: 0028234390
PISSN: 03603016
EISSN: None
Source Type: Journal
DOI: 10.1016/0360-3016(94)90292-5 Document Type: Article |
Times cited : (64)
|
References (12)
|